Understand testosterone results through symptoms, reference thresholds, repeat testing, sampling conditions and the selective use of related hormone markers.
A testosterone blood test measures testosterone in a blood sample at a particular time and under particular conditions. Total testosterone is often the starting measurement when a clinician assesses possible testosterone deficiency.
This article is for informational purposes only and is not medical advice. A qualified clinician should interpret your results and decide whether further testing or treatment is appropriate.
A laboratory reference range is the comparison interval shown beside a test result. For testosterone, the result describes a concentration in blood. It is not a score for energy, sexual function or physical strength.
The European Association of Urology (EAU) uses 12 nmol/L as a threshold in its recommendations for late-onset hypogonadism. The unit nmol/L expresses the concentration of testosterone in the sample. That threshold belongs to a clinical assessment framework rather than being an ideal value for every man.
A diagnostic threshold and a laboratory reference interval are not interchangeable. The EAU threshold should not be presented as a complete normal range with a universal upper boundary. The laboratory's own interval and measurement method remain part of interpreting the report.
The EAU recommends diagnosing testosterone deficiency through compatible symptoms or signs together with consistently low morning testosterone. Measurements should be taken on at least two occasions using a reliable assay. This is why a laboratory flag alone does not establish hypogonadism.
An assay is the laboratory method used to measure a substance. The EAU describes LC-MS/MS as the most accurate method for evaluating sex steroids. It also states that standardized automated immunoassays for total testosterone correlate well with that method.
That distinction does not mean routine immunoassays should automatically be dismissed. Instead, questions about the measurement method belong in the interpretation of the result. The guideline recommends collaboration between clinicians and laboratories to support accurate and comparable measurements.
When comparing reports, the useful question is whether the results were obtained under comparable conditions and with suitable methods. Treating every difference between reports as a biological change skips that laboratory context.
Sex hormone-binding globulin, usually called SHBG, is a binding protein relevant to testosterone interpretation. The EAU recommends measuring SHBG and calculating free testosterone when indicated. This is particularly relevant when a condition may alter SHBG.
The method used for free testosterone also matters. The guideline describes equilibrium dialysis as the most accurate measurement method. It does not recommend direct free-testosterone estimates from available immunoassays.
A report labelled “free testosterone” therefore deserves a question about how that value was obtained. The label alone does not explain the method. Understanding the different questions answered by hormone markers helps keep the discussion focused on clinical interpretation rather than collecting more numbers.
Other markers help investigate the cause of an abnormal result. The EAU recommends LH and FSH to help distinguish types of hypogonadism. It also recommends measuring LH with prolactin when pathological total testosterone is detected.
These tests have different purposes. SHBG and free testosterone can clarify testosterone interpretation when binding proteins are relevant. LH, FSH and prolactin contribute to investigating the underlying clinical picture. Their inclusion should answer a defined question rather than create a larger collection of targets.
The EAU identifies several sexual symptoms as more specific to testosterone deficiency than general changes in energy or physical performance:
“More specific” does not mean that these symptoms establish a hormonal diagnosis. The guideline notes that symptoms associated with late-onset hypogonadism are not exclusive to it. They need to be considered alongside the clinical assessment and blood results.
Low energy and reduced physical strength or activity are among the less specific symptoms listed by the EAU. A man who feels tired or less physically capable therefore needs assessment of the concern itself. Those experiences should not automatically be assigned to testosterone.
The same reasoning matters when a result falls within the laboratory interval. A number in that interval is not a reason to dismiss persistent symptoms. The clinical task is to understand the symptoms rather than make them fit a preferred explanation.
For a result above the laboratory interval, the deficiency symptom list should not simply be read in reverse. That result needs its own interpretation in the context of the sample and the clinical assessment.
For sexual concerns, describing the actual change is more useful than using “low T” as a shorthand. Readers preparing that conversation can find further context on testosterone's relationship with changes in desire.
The EAU identifies several influences that can affect the measurement or the way it should be understood. Some concern the blood draw itself. Others concern binding proteins and the broader physiological setting.
The food-related finding does not mean that eating before a test reduces every man's result by the same amount. Its practical significance is that fasting status belongs in the record used to interpret the measurement. It is not a basis for calculating a corrected result at home.
Sleep timing deserves similar attention. For night-shift workers, the EAU says sampling should follow adequate sleep and fasting conditions. A clock time that fits the general population may not describe the same biological circumstances for someone whose main sleep occurs during the day.
Acute illness is another reason to discuss the timing of a test with the clinician. An illness-associated result needs that context recorded. The guideline's recommendation concerns when to measure testosterone rather than a rule that every unexpected reading should be ignored.
The EAU lists several factors associated with altered SHBG:
These associations help explain why total testosterone sometimes needs additional context. They do not mean that a total testosterone result can identify a thyroid condition or explain body weight. The relevant clinical question is whether altered SHBG makes free-testosterone calculation useful in that assessment.
This also separates two different issues: a factor affecting the circumstances of measurement and a factor affecting interpretation through a binding protein. A non-fasting sample and altered SHBG are not the same problem. They call for different questions about what the result represents.
A useful discussion starts with the report and the circumstances surrounding it. Relevant details include the sample time and fasting status. Acute illness and unusual sleep timing are also worth documenting because the guideline identifies them as important considerations.
For a low result, the EAU recommends confirmation with a repeat measurement before testosterone therapy is started. The purpose is to establish a consistent finding under appropriate conditions. Repeated sampling is therefore part of assessment rather than simply an attempt to obtain a preferred number.
A clinician can also explain whether the next question concerns confirmation or investigation of the cause. Those are different stages of reasoning. Repeating total testosterone addresses consistency, while selected related markers may address interpretation or the type of abnormality.
For more background on that process, Testostra explains why repeat blood draws and laboratory context matter. The useful outcome is a result that can be interpreted alongside symptoms and testing conditions.
Ask: “Which laboratory interval and clinical threshold apply here? Do my symptoms support further assessment? Should this result be repeated under comparable conditions? Would SHBG and free testosterone clarify it? What would LH, FSH or prolactin investigate?”
Comparing repeat testosterone measurements in their testing context provides a concrete starting point for understanding a result, and Testostra explains the relevant evidence. For men unsure how SHBG relates to total and free testosterone, its biomarker coverage clarifies those relationships while distinguishing established clinical guidance from emerging findings and keeping individual diagnosis outside its educational role.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra